MISSION

“Shaping oncology innovation”. Our commitment.

Intellectual property

High value organization for oncology innovation

About us

Fully integrated platform for R&D value chain

Results

Proved track record, high quality standards and fully compliant services.

Delivering innovative drugs and high quality CRO e CDMO services

Mission

The mission of NMS Group is to discover and develop new molecules and therapeutic strategies, contributing to shape the future of cancer care. Thanks to its unique fully integrated R&D chain, the Group is also committed in offering high quality pre-clinical, clinical and production services at a global level.
The vast scientific heritage of internal skills, technology and experience represents our excellence and the basis for achieving our goals with continuous commitment and enthusiasm.

NMS Group is the largest company in Italy committed in innovation and research and development in oncology.

About us

Our company is a high value organization covering the whole R&D process: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug. Nerviano Medical Sciences represents the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. NMS Group also provides Research and Production services, addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

Our numbers

About us

 
Licensing
+  
Active patents and
patent applications
+  
Published
papers
+  
People
+  
Pre clinical
studies/year
+  
Overall worldwide collaborations with research & care Centers
 
Production
plants

Press Release & News >

Nerviano, Italy, 01.06.2018

Nerviano Medical Sciences announces Collaboration and License Agreement with Merck to discover small molecule inhibitors of certain anticancer targets

Today Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors of certain molecular targets in the area of DNA damage repair.
Read more +
Nerviano, Italy, 16.04.2018

THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS AWARD TO A SCIENTIST FROM NERVIANO MEDICAL SCIENCES AT ITS ANNUAL MEETING

Elena Ardini, a biologist at Nerviano Medical Sciences, is the first author of a scientific publication by our group selected for inclusion in this year’s "Best of the AACR Journals Collection". The article entitled “Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications” appeared in the AACR Journal “Molecular Cancer Therapeutics” in 2016 and became its most cited publication of that year. Entrectinib, a molecule discovered, developed and brought to the clinic by Nerviano Medical Scieces showcases the scientific excellence and drug discovery/development expertise of the Nerviano Campus.
Read more +
Nerviano, Italy, 05.04.2018

Nerviano Researchers’ Contribution in Building Anticancer Drug Actions Atlas

This is the most complete study carried out, up to date, on kinases and over 240 inhibitors and it illustrates how new opportunities for cancer treatment could arise from some kinase inhibitors already approved or currently in clinical development phase. Involved four experienced researchers from Nerviano Campus, highly regarded in the field of kinase biochemistry and structural chemistry.
Read more +